Biotechnology - Biotechnology, Exelixis

Filter

Current filters:

BiotechnologyExelixis

Popular Filters

EU approval for Cometriq in medullary thyroid carcinoma

EU approval for Cometriq in medullary thyroid carcinoma

25-03-2014

The European Commission has approved Cometriq (cabozantinib), a drug for the treatment of adult patients…

BiotechnologyCometriqEuropeExelixisOncologyRegulationSwedish Orphan Biovitrum

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

13-02-2014

Exelixis (NASDAQ: EXEL) have announced the appointment of Jeffrey Hessekiel as executive vice president…

BiotechnologyBoardroomExelixisOncologyUSA

SOBI to distribute Exelixis' cancer drug Cometriq in EU

22-02-2013

US biotech firm Exelixis (Nasdaq: EXEL) has entered into a three-year with Swedish Orphan Biovitrum (STO:…

BiotechnologyCometriqEuropeExelixisLicensingOncologySobiSwedish Orphan Biovitrum

FDA approves Exelixis' Cometriq for rare thyroid cancer, as EMA accepts filing

30-11-2012

There were two items of good news yesterday for US drug developer Exelixis' (Nasdaq: EXEL), the first…

AstraZenecaBiotechnologycabozantinibCaprelsaCometriqEuropeExelixisNorth AmericaOncologyPharmaceuticalRegulation

Exelixis and Sanofi terminate $1 billion cancer deal

23-12-2011

US biotechnology firm Exelixis (Nasdaq: EXEL) says its oncology deal with French drug Major Sanofi (Euronext:…

BiotechnologyExelixisLicensingOncologyPharmaceuticalResearchSanofi

Sanofi names David Meeker as chief executive of Genzyme; Exelixis hires former Genentech exec

25-10-2011

French drug major Sanofi (Euronext: SAN) has appointed David Meeker as chief executive of its USA-based…

BiotechnologycabozantinibExelixisGenzymeManagementPharmaceuticalSanofi

Back to top